PNC Financial Services Group’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $261K | Buy |
10,554
+474
| +5% | +$11.3K | ﹤0.01% | 2146 |
|
|
2025
Q4 | $235K | Buy |
10,080
+714
| +8% | +$15.9K | ﹤0.01% | 2181 |
|
|
2025
Q3 | $185K | Buy |
9,366
+3,511
| +60% | +$72.2K | ﹤0.01% | 2357 |
|
|
2025
Q2 | $127K | Buy |
5,855
+354
| +6% | +$8.36K | ﹤0.01% | 2532 |
|
|
2025
Q1 | $133K | Buy |
5,501
+2,002
| +57% | +$45.1K | ﹤0.01% | 2467 |
|
|
2024
Q4 | $73K | Buy |
3,499
+289
| +9% | +$6.21K | ﹤0.01% | 2881 |
|
|
2024
Q3 | $63.8K | Buy |
3,210
+503
| +19% | +$9.32K | ﹤0.01% | 2949 |
|
|
2024
Q2 | $41.9K | Buy |
2,707
+125
| +5% | +$1.95K | ﹤0.01% | 3120 |
|
|
2024
Q1 | $41.2K | Sell |
2,582
-10,378
| -80% | -$156K | ﹤0.01% | 3085 |
|
|
2023
Q4 | $218K | Buy |
12,960
+1,719
| +15% | +$23.5K | ﹤0.01% | 2089 |
|
|
2023
Q3 | $131K | Buy |
11,241
+3,354
| +43% | +$44.9K | ﹤0.01% | 2394 |
|
|
2023
Q2 | $106K | Buy |
7,887
+4,728
| +150% | +$68K | ﹤0.01% | 2614 |
|
|
2023
Q1 | $52.4K | Buy |
3,159
+64
| +2% | +$1.06K | ﹤0.01% | 2974 |
|
|
2022
Q4 | $57.6K | Buy |
3,095
+315
| +11% | +$4.85K | ﹤0.01% | 2894 |
|
|
2022
Q3 | $36K | Buy |
2,780
+2,374
| +585% | +$28.1K | ﹤0.01% | 3154 |
|
|
2022
Q2 | $2K | Hold |
406
| – | – | ﹤0.01% | 4182 |
|
|
2022
Q1 | $4K | Hold |
406
| – | – | ﹤0.01% | 4044 |
|
|
2021
Q4 | $2K | Buy |
+406
| New | +$2.67K | ﹤0.01% | 4133 |
|
|
2019
Q4 | – | Sell |
-259,122
| Closed | -$1.38M | – | 4001 |
|
|
2019
Q3 | $1.38M | Buy |
+259,122
| New | +$1.38M | ﹤0.01% | 1127 |
|
|
2018
Q3 | – | Sell |
-1,000
| Closed | -$3K | – | 4124 |
|
|
2018
Q2 | $3K | Buy |
+1,000
| New | +$3.03K | ﹤0.01% | 3927 |
|
|
2015
Q3 | – | Sell |
-1,000
| Closed | -$4K | – | 4625 |
|
|
2015
Q2 | $4K | Buy |
+1,000
| New | +$3.99K | ﹤0.01% | 4151 |
|
Other funds holding CPRX
VCM
DM
VPM